Novartis’s failed trial for cholesterol drug leads to broad biopharma stock selloff

The failed trial of Novartis's cholesterol drug has sent shockwaves through the biopharma sector, leading to a widespread selloff as investors reassess the viability of similar cardiovascular treatments. This setback highlights the unpredictable nature of drug development and the significant financial risks involved, prompting a reevaluation of biotech stocks across the board. The trial's failure underscores the challenges in tackling complex cardiovascular risks and could impact future research and funding in this area.